Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study
Table 4
Comparison between overweight and obese patients with NASH and overweight and obese patients without NASH.
Variable
NASH patients
Non-NASH patients
value
Boys (, %)
4 (57.1%)
31 (50.8%)
1.00
Age (years)
10 (7)
10 (6)
0.28
Weight percentile
90th (9)
97th (4)
0.07
Waist percentile
95th (6)
95th (6)
0.82
Midarm circumference centile
75th (49)
95th (8)
0.07
BMI (kg/m2)
27.30 (10.70)
25 (5.95)
0.96
BMI percentile
96th (10)
98th (3)
0.062
BMI -score
1.80 (0.98)
2.04 (0.68)
0.088
WtHR
60.99 (12.56)
59.10 (6.80)
0.84
Total cholesterol (mg/dL)
169 (38)
162 (54)
0.67
LDL cholesterol (mg/dL)
108 (35)
99.5 (38)
0.52
HDL cholesterol (mg/dL)
34 (23)
43 (19)
0.08
Triglyceride (mg/dL)
134 (58)
91 (70)
0.07
Non-HDL cholesterol (mg/dL)
135 (33)
119 (44)
0.21
Triglyceride/HDL cholesterol ratio
3.53 (0.97)
2 (1.99)
0.034
C-reactive protein (mg/dL)
0.71 (0.91)
0.38 (0.92)
0.88
Fasting glucose (mg/dL)
87 (19)
89 (10)
0.70
ASAT (UI/L)
52 (33)
22 (7)
0.001
ALAT (UI/L)
92 (60)
28 (12)
<0.001
Alkaline phosphatase (UI/L)
232.5 (165)
243 (129)
0.81
Uric acid (mg/dL)
4.05 (3.9)
4.80 (2.3)
0.42
Obese (, %)
4 (57.1%)
55 (90.2%)
0.045
Insulin (mU/L)
14.81 (21.38)
9.67 (13.74)
0.88
HOMA-IR
3.15 (4.53)
2.13 (2.86)
0.84
Endocan (ng/mL)
1.86 (0.24)
2.83 (1.82)
0.026
Lumican (ng/mL)
9.82 (11.35)
12.07 (6.24)
0.46
Hypertension (, %)
3 (42.9%)
30 (49.2%)
1.00
Systolic blood pressure centile
50th (45)
50th (43)
0.89
Diastolic blood pressure centile
90th (45)
50th (45)
0.83
Data are presented as median (interquartile range). BMI: body mass index; WtHR: waist to height ratio; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HDL: high-density lipoprotein; LDL: low-density lipoprotein; HOMA-IR: Homeostatic Model Assessment of Insulin Resistance. values were computed with Mann-Whitney tests for continuous variables and Fisher exact test for nominal variables.
